Pharmacoeconomic profile of patients with chronic kidney failure undergoing hemodialysis at a regional public hospital at Toto Kabila Gorontalo, Indonesia
Journal of Renal Injury Prevention · 09.08.2025 · 15 (1) · e38390
DOI: 10.34172/jrip.2025.38390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Renal Injury Prevention, online erschienen am 09.08.2025. Verfasst von Madania Madania und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
One of the non-communicable diseases that requires significant costs due to its long treatment duration and expensive equipment is chronic kidney disease (CKD). The high cost of treatment for patients with CKD undergoing hemodialysis drives the need for a pharmacoeconomic review, as individuals face limited resources and treatment costs continue to rise over time.
Objectives
The aim of this study is to determine the total costs for CKD patients undergoing hemodialysis, analyze the minimal costs and cost-effectiveness, and to assess the utility of hemodialysis patients. Patients and Methods: This study is an observational study using secondary data obtained from patient’s medical records and hospital financial data, as well as primary data through interviews and questionnaires. The entire population was taken as a sample, consisting of 34 CKD patients undergoing hemodialysis. The cost of illness (COI) was determined by calculating the total costs, minimal costs by calculating fixed and variable costs, cost-effectiveness by calculating average cost effectiveness ratio (ACER) and incremental cost effectiveness ratio (ICER), and also cost-utility analysis (CUA) using the EQ-5D-5L and visual analog scale (VAS) questionnaires.
Results
The research results showed that the COI for hemodialysis patients was USD 3884.27. The antihypertensive drug amlodipine was the more cost-minimizing and most cost-effective option compared to candesartan. The average utility value for hemodialysis patients was 0.692 (feeling fairly healthy), and the VAS utility score was 72.3 (moderately healthy health status).
Conclusion
The pharmacoeconomic profile, including COI, cost minimization analysis (CMA), cost-effectiveness analysis (CEA), and CUA, are interrelated. The costs incurred by patients, along with the financial and health-related losses due to illness, impact the quality of life of CKD patients undergoing hemodialysis.
Zitieren
APA
Madania, M., Tuloli, T. S., Mo’o, F. R. C., Adriani, A., Busura, T. S. N., Paputungan, S. A. Q., & Maghfirah, S. N. (2025). Pharmacoeconomic profile of patients with chronic kidney failure undergoing hemodialysis at a regional public hospital at Toto Kabila Gorontalo, Indonesia. Journal of Renal Injury Prevention, 15(1), e38390. https://doi.org/10.34172/jrip.2025.38390
Vancouver
Madania M, Tuloli TS, Mo’o FRC, Adriani A, Busura TSN, Paputungan SAQ, et al. Pharmacoeconomic profile of patients with chronic kidney failure undergoing hemodialysis at a regional public hospital at Toto Kabila Gorontalo, Indonesia. Journal of Renal Injury Prevention. 2025;15(1):e38390. doi:10.34172/jrip.2025.38390
BibTeX
@article{Madania2025,
author = {Madania, Madania and Tuloli, Teti Sutriyati and Mo’o, Faradila Ratu Cindana and Adriani, Adriani and Busura, Tarriza Salsabila Nurlaila and Paputungan, Siti Azzahra Qhorisyah and Maghfirah, Siti Nur},
title = {Pharmacoeconomic profile of patients with chronic kidney failure undergoing hemodialysis at a regional public hospital at Toto Kabila Gorontalo, Indonesia},
journal = {Journal of Renal Injury Prevention},
year = {2025},
volume = {15},
number = {1},
pages = {e38390},
doi = {10.34172/jrip.2025.38390}
}
EUVIMED